FGFR1 and non-small cell lung carcinoma: Although most compounds demonstrated a modest inhibition of FGFR1, compound C9 showed excellent inhibition of five NSCLC cell lines with FGFR1 amplification, which was significantly better than the lead compound SSR128129E.